🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareRetatrutide anticipation thread — what are your questions for Phase 3? Page 4

Retatrutide anticipation thread — what are your questions for Phase 3?

rick_sfbay Mon, Mar 23, 2026 at 11:14 PM 32 replies 903 viewsPage 4 of 7
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Mar 30, 2026 at 2:07 AM#16

Adding the clinical framing, because it changes how the question reads. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

25 23DerekSJ_a1c, paige_pharma, emma_london and 22 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Mar 31, 2026 at 1:39 AM#17

Adding the clinical framing, because it changes how the question reads. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

26 24PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 23 others
Reply Quote Save Share Report
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Apr 1, 2026 at 1:10 AM#18
Dr.ObesityMed said:
It helps to say which part of this you are uncertain about.

Mine went the same way, slower.

27 0mona_PHX, andrew_nyc, Dr.EndoEP and 24 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Apr 2, 2026 at 12:41 AM#19
Dr.ObesityMed said:
It helps to say which part of this you are uncertain about.

Coming at Dr.ObesityMed’s question from a different direction. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.

28 1Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 25 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Apr 3, 2026 at 12:11 AM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out. Carry on.

50 23PurityPaulOR, MaxMetOK, MounjBrad and 47 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register